Cargando…

Paediatric Fabry disease: prognostic significance of ocular changes for disease severity

BACKGROUND: Ocular signs of Fabry disease can be seen in the first decade of life. METHODS: We examined the occurrence of ocular signs in 232 paediatric patients in the Fabry Outcome Survey (FOS) international registry and looked for relationships between the presence of eye findings and disease sev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalkum, Gisela, Pitz, Susanne, Karabul, Nesrin, Beck, Michael, Pintos-Morell, Guillem, Parini, Rossella, Rohrbach, Marianne, Bizjajeva, Svetlana, Ramaswami, Uma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5112699/ https://www.ncbi.nlm.nih.gov/pubmed/27852300 http://dx.doi.org/10.1186/s12886-016-0374-2

Ejemplares similares

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
por: Ramaswami, Uma, et al.
Publicado: (2012)

Ocular Signs Correlate Well with Disease Severity and Genotype in Fabry Disease
por: Pitz, Susanne, et al.
Publicado: (2015)

Analysis of Renal and Cardiac Outcomes in Male Participants in the Fabry Outcome Survey Starting Agalsidase Alfa Enzyme Replacement Therapy Before and After 18 Years of Age
por: Parini, Rossella, et al.
Publicado: (2020)

Fabry disease in children and the effects of enzyme replacement treatment
por: Pintos-Morell, Guillem, et al.
Publicado: (2009)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
por: Barba-Romero, Miguel-Ángel, et al.
Publicado: (2016)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Spanish Fabry and Gaucher disease patients show striking differences in Beliefs about Medicines (BMQ) and Brief Illness Perception (BIPQ) questionnaires
por: González-Lamuño, Domingo, et al.
Publicado: (2022)

Update on role of agalsidase alfa in management of Fabry disease
por: Ramaswami, Uma
Publicado: (2011)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events
por: Beck, Michael, et al.
Publicado: (2017)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry
por: Beck, Michael, et al.
Publicado: (2022)

Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease
por: Lenders, Malte, et al.
Publicado: (2016)

Translation of quality of life scale for pediatric patients with Fabry disease in Japan
por: Koto, Yuta, et al.
Publicado: (2022)

Biomarkers in Fabry Disease. Implications for Clinical Diagnosis and Follow-up
por: Carnicer-Cáceres, Clara, et al.
Publicado: (2021)

Ocular findings in Fabry disease in Colombian patients
por: Rothstein, Katherine, et al.
Publicado: (2019)

Investigation of ocular involvement in patients with Fabry disease
por: Wu, Yuan, et al.
Publicado: (2023)

Characterization of Early Disease Status in Treatment-Naive Male Paediatric Patients with Fabry Disease Enrolled in a Randomized Clinical Trial
por: Wijburg, Frits A., et al.
Publicado: (2015)

Cardiac Phenotype of Prehypertrophic Fabry Disease
por: Nordin, Sabrina, et al.
Publicado: (2018)

Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease
por: Avarappattu, Jenny, et al.
Publicado: (2023)

Fabry disease: a survey of visual and ocular symptoms
por: Davey, Pinakin Gunvant
Publicado: (2014)

Extent, impact, and predictors of diagnostic delay in Pompe disease: A combined survey approach to unveil the diagnostic odyssey
por: Lagler, Florian B., et al.
Publicado: (2019)

Home treatment for lysosomal diseases during COVID-19: German experience
por: Karabul, Nesrin, et al.
Publicado: (2021)

Ocular manifestations in a patient with de novo Fabry disease
por: Lee, You Hyun, et al.
Publicado: (2018)

Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients
por: Germain, Dominique P., et al.
Publicado: (2019)

A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation
por: Lee, Han-Jui, et al.
Publicado: (2017)

Longitudinal study on ocular manifestations in a cohort of patients with Fabry disease
por: Michaud, Langis
Publicado: (2019)

Polyarticular arthritis as presenting feature of farber disease: a lysosomal storage disease involving inflammation
por: Sólyom, Alexander, et al.
Publicado: (2014)

Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel
por: Stepien, Karolina M., et al.
Publicado: (2023)

Correlation of retinal vascular characteristics with laboratory and ocular findings in Fabry disease: exploring ocular diagnostic biomarkers
por: Lindziute, Migle, et al.
Publicado: (2023)

The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data
por: Ramaswami, Uma, et al.
Publicado: (2017)

Transition of patients with metabolic bone disease from paediatric to adult healthcare services: current situation and proposals for improvement
por: Casado, Enrique, et al.
Publicado: (2023)

Rats deficient in α-galactosidase A develop ocular manifestations of Fabry disease
por: Miller, James J., et al.
Publicado: (2019)

Autophagy-lysosome pathway alteration in ocular surface manifestations in Fabry disease patients
por: Marenco, Marco, et al.
Publicado: (2022)

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
por: Augusto, João B, et al.
Publicado: (2020)

Correlations between Endomyocardial Biopsies and Cardiac Manifestations in Taiwanese Patients with the Chinese Hotspot IVS4+919G>A Mutation: Data from the Fabry Outcome Survey
por: Hsu, Ting-Rong, et al.
Publicado: (2017)

Comment: Why are females with Fabry disease affected?
por: Beck, Michael, et al.
Publicado: (2019)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
por: Nordin, Sabrina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ev70u67gu6habl7ulc3iud0hpk